CarlsmedvsMerck & Company

CARL and MRK stock compared: price, dividend, valuation and results, from SEC filings.

CARL

Carlsmed, Inc.

$17.37

Value $464M

-2.09%
CARL's page

MRK

Merck & Company, Inc.

$137.78

Value $341B

-3.90%
MRK's page

Carlsmed (CARL) has a market value of $464M and Merck & Company (MRK) $341B. Over the last year, with dividends, CARL moved +41.1% and MRK +52.7%. Dividend yield: CARL none, MRK 2.47%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    CARL$464M

    MRK$341B

    MRK is 734 times CARL

  • Revenue, 12 months

    CARL$72M

    MRK$67.4B

    MRK is 939 times CARL

  • Net income, 12 months

    CARL-$40M

    MRK$2.5B

  • Operating margin

    CARL-59.0%

    MRK–

  • ROIC

    CARL-31.3%

    MRK3.9%

    35.2 points apart

  • P/E

    CARL–

    MRK138.9

  • Dividend yield

    CARL0.0%

    MRK2.5%

    2.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

CARL+41.1%

MRK+52.7%

100150DecFebAprJunAugOct
Returns by period
PeriodCARLWith dividendsMRKWith dividends
1 year since November 17, 2025+41.1%Price +41.1%+52.7%Price +48.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

CARLCarlsmedMRKMerck & Company

Valuation

CARLMRK
Valuation
Price$17.37$137.78
Market value$464M$341B
Enterprise value (EV)$420M$385B
P/E–138.9
P/E, 5-year median–14.8
P/B6.17.6
EV/EBIT–80.8
Free cash flow yield–4.3%

Results and growth

CARLMRK
Results and growth
Revenue, 12 months$72M$67.4B
Net income, 12 months-$40M$2.5B
Free cash flow, 12 months-$35M$14.7B
Earnings per share, 12 months-$1.13$0.98
Revenue growth, year on year85.9%1.3%
Revenue growth a year, past+85.9%over 1 years+9.4%over 5 years
EPS growth a year, past–+21.2%over 5 years

Margins and returns on capital

CARLMRK
Margins and returns on capital
Gross margin77.0%71.8%
Operating margin-59.0%–
Net margin-55.8%3.6%
ROIC-31.3%3.9%
ROE-43.8%5.2%

Balance sheet

CARLMRK
Balance sheet
Cash$60M$9.7B
Total debt$22M$53.8B
Net debt / EBITDA–5.7
Interest cover-33.3×2.4×

Dividends and buybacks

CARLMRK
Dividends and buybacks
Dividend yield–2.5%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield–1.5%
Shareholder yield–4.0%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: CARL or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, Carlsmed or Merck & Company?

By market value, Merck & Company ($341B) is about 733.6 times Carlsmed ($464M), at today's prices.

How did CARL and MRK stock do over the last 1 years?

Since November 17, 2025, CARL's price moved +41.1% and MRK's +48.4%. With dividends: CARL +41.1% (+41.1% a year), MRK +52.7% (+52.7% a year). Past returns do not predict future ones.

Which pays the higher dividend, CARL or MRK?

The dividend yield at today's price is none for Carlsmed and 2.47% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

Which has the higher profit margins, Carlsmed or Merck & Company?

Over the last twelve months, the net margin was -55.8% for Carlsmed and 3.6% for Merck & Company, and the operating margin -59.0% and –. Revenue was $72M and $67.4B.

Which is the better investment, Carlsmed or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.